Pharsight

Drugs that contain Rosuvastatin Calcium

1. Crestor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE37314 IPR Pyrimidine derivatives
Jan, 2016

(8 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE37314

(Pediatric)

IPR Pyrimidine derivatives
Jul, 2016

(7 years ago)

US7030152 IPR Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Apr, 2018

(6 years ago)

US7964614 IPR Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Apr, 2018

(6 years ago)

US7964614

(Pediatric)

IPR Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Oct, 2018

(5 years ago)

US7030152

(Pediatric)

IPR Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Oct, 2018

(5 years ago)

US6316460 IPR Pharmaceutical compositions
Aug, 2020

(3 years ago)

US6316460

(Pediatric)

IPR Pharmaceutical compositions
Feb, 2021

(3 years ago)

US6858618 IPR Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
Dec, 2021

(2 years ago)

US6858618

(Pediatric)

IPR Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
Jun, 2022

(1 year, 10 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-573) Nov 06, 2011
Orphan Drug Exclusivity(ODE) May 27, 2023
New Indication(I-732) May 27, 2019
New Patient Population(NPP) Nov 20, 2018
Orphan Drug Exclusivity(ODE-118) May 27, 2023
New Indication(I-621) Feb 08, 2013
New Indication(I-611) Oct 16, 2012
Pediatric Exclusivity(PED) Apr 16, 2013

Market Authorisation Date: 12 August, 2003

Treatment: Use of rosuvastatin calcium for the primary prevention of cardiovascular disease in individuals without clinically evident coronary heart disease but with increased risk factors; Use of rosuvastatin c...

Dosage: TABLET;ORAL

How can I launch a generic of CRESTOR before it's drug patent expiration?
More Information on Dosage

CRESTOR family patents

Family Patents

2. Ezallor Sprinkle patents expiration

Can you believe EZALLOR SPRINKLE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10413543 SUN PHARM Stable multiparticulate pharmaceutical composition of rosuvastatin
Feb, 2036

(11 years from now)

Market Authorisation Date: 18 December, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

EZALLOR SPRINKLE family patents

Family Patents